HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

RSVA314

an AMPK activator; structure in first source

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Marambaud, Philippe: 2 articles (02/2015 - 09/2011)
2.	Coppa, Gene F: 1 article (02/2015)
3.	Khader, Adam: 1 article (02/2015)
4.	Kuncewitch, Michael: 1 article (02/2015)
5.	Nicastro, Jeffrey: 1 article (02/2015)
6.	Prince, Jose M: 1 article (02/2015)
7.	Wang, Ping: 1 article (02/2015)
8.	Yang, Weng-Lang: 1 article (02/2015)
9.	Chandakkar, Pallavi: 1 article (09/2011)
10.	Davies, Peter: 1 article (09/2011)

Related Diseases

1.	Obesity 09/01/2011 - "This work shows that the novel small-molecule activators of AMPK (RSVA314 and RSVA405) are potent inhibitors of adipogenesis and thus may have therapeutic potential against obesity."
2.	Ischemia 02/01/2015 - "RSVA405 (3 mg/kg Body Weight), RSVA314 (3 mg/kg Body Weight), or vehicle (10% dimethyl sulfoxide and 33% Solutol in phosphate buffered saline) were administered by intraperitoneal injection 1 h before ischemia. "
3.	Inflammation (Inflammations) 02/01/2015 - "RSVA405 and RSVA314 attenuate I/R-induced renal injury through the modulation of energy metabolism, oxidative stress, and inflammation."
4.	Body Weight (Weight, Body) 02/01/2015 - "RSVA405 (3 mg/kg Body Weight), RSVA314 (3 mg/kg Body Weight), or vehicle (10% dimethyl sulfoxide and 33% Solutol in phosphate buffered saline) were administered by intraperitoneal injection 1 h before ischemia. "

Related Drugs and Biologics

1.	RSVA405
2.	Phosphates (Orthophosphate)
3.	Dimethyl Sulfoxide (DMSO)

Related Therapies and Procedures

1.	Intraperitoneal Injections